Compare BioNano Genomics Inc (BNGO) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Invesco S&P 500 Momentum ETF — how do they compare? BioNano Genomics Inc trades at $1.16 (market cap $13.77M), while Invesco S&P 500 Momentum ETF trades at $152.94. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPMO | |
|---|---|---|
Market Cap | $13.77M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $161.66 |
52-Week Low | $1.06 | $107.84 |
Enterprise Value | $16.38M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
SPMO is trading at $151.21, up 1.69% with strong momentum characteristics. The ETF has demonstrated significant outperformance versus the S&P 500, gaining 26% year-to-date according to 24/7 Wall Street (2026-07-20). Technical indicators show a bullish trend with support at $147-148 and resistance at $149-151, though RSI levels suggest potential near-term consolidation.
The momentum-focused strategy continues to deliver alpha through concentrated technology exposure, particularly AI beneficiaries. However, high concentration risk and sector rotation vulnerability present challenges. With institutional interest growing and momentum factor dominance persisting, SPMO offers strategic exposure to market leaders but requires monitoring for momentum shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
